Clinical & Dermatologic Review — 2024–2026
Cutaneous Biology, Hair Physiology &
Emerging Dermatologic Implications
GLP-1 receptor agonists have redefined the pharmacotherapy of type 2 diabetes and obesity. Their pleiotropic effects now extend into dermatology, altering the very biology of skin and hair in ways both beneficial and adverse.
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) represent a paradigm shift in the management of metabolic disease. Initially developed as incretin mimetics to lower postprandial glucose, their effects on appetite regulation, weight reduction, cardiovascular risk, and systemic inflammation have broadened their clinical use exponentially. By 2025–2026, semaglutide (Ozempic/Wegovy), liraglutide (Victoza/Saxenda), and tirzepatide (Mounjaro/Zepbound) have become among the most widely prescribed pharmaceuticals globally.
As prescriptions have scaled, dermatologists and trichologists have begun observing a constellation of cutaneous effects — some clearly beneficial (improvement of inflammatory skin diseases tied to metabolic syndrome, resolution of acanthosis nigricans, reduction of systemic inflammation), and others presenting clinical challenges (telogen effluvium from rapid weight loss, injection-site reactions, and rare immune-related phenomena).
GLP-1 receptors (GLP1R) are expressed not only in pancreatic beta-cells but also in keratinocytes, dermal fibroblasts, sebaceous glands, and hair follicle stem cells — establishing a direct biological rationale for cutaneous effects that extends beyond systemic metabolic changes alone.
This review synthesizes current evidence through early 2026, covering the molecular pharmacology of GLP-1 RAs, their direct and indirect effects on skin physiology, the trichologic consequences (particularly drug-related telogen effluvium and emerging data on androgenetic alopecia), and practical management strategies for dermatologic providers.
Understanding the pleiotropy of GLP-1 RA effects requires appreciating both their primary incretin pharmacology and the breadth of GLP-1R tissue distribution.
Glucagon-like peptide-1 is a 30-amino-acid incretin hormone secreted primarily by enteroendocrine L-cells of the distal ileum and colon in response to nutrient ingestion. Endogenous GLP-1 has a plasma half-life of 1–2 minutes due to rapid inactivation by dipeptidyl peptidase-4 (DPP-4). Pharmacologic GLP-1 RAs are structural analogues resistant to DPP-4 degradation, enabling sustained receptor activation and downstream signaling across multiple organ systems.
GLP-1R is a Gs-coupled GPCR. Activation elevates intracellular cyclic AMP (cAMP), which activates protein kinase A (PKA) and exchange protein directly activated by cAMP (Epac). In keratinocytes and follicular cells, this cascade intersects with:
Cutaneous effects of GLP-1 RAs arise through three overlapping channels: systemic metabolic improvement, direct receptor-mediated skin signaling, and structural changes from significant weight loss.
Acanthosis nigricans (AN) — velvety, hyperpigmented plaques at skin flexures — is intimately tied to hyperinsulinemia. Insulin and IGF-1 drive keratinocyte proliferation via insulin receptor and IGF-1R. GLP-1 RAs dramatically reduce fasting insulin levels and insulin resistance. Multiple case series and retrospective cohorts confirm partial-to-complete resolution of AN within 6–18 months in patients achieving significant weight reduction and glycemic control, consistent with HOMA-IR normalization.
Obese and diabetic patients exhibit impaired epidermal barrier function marked by reduced filaggrin expression, elevated transepidermal water loss (TEWL), and altered ceramide composition. GLP-1 RA–mediated improvement in metabolic parameters restores these deficits. Emerging in vitro data demonstrate that direct GLP-1R activation in keratinocytes upregulates involucrin and filaggrin gene expression independently of systemic effects.
Diabetic foot ulcers and poor wound healing represent major complications of metabolic disease. GLP-1 RAs accelerate wound closure through: (a) improved microvascular perfusion via NO-dependent vasodilation, (b) reduced AGE-RAGE axis activation, (c) anti-inflammatory macrophage polarization promoting M2 phenotype at wound sites, and (d) direct promotion of dermal fibroblast migration and collagen synthesis. A 2024 randomized trial in diabetic patients with chronic wounds showed significantly faster re-epithelialization in semaglutide-treated groups versus placebo.
Weight loss and metabolic improvement with GLP-1 RAs result in lower circulating pro-inflammatory cytokines (CRP, IL-6, TNF-α) that drive inflammaging. Skin biopsies in long-term semaglutide-treated patients (STEP program substudies, 2023–2025) show measurable increases in dermal collagen density and hyaluronic acid content. Reductions in visceral adiposity decrease systemic adipokine-driven senescence signaling in skin cells. Clinically, many patients report improved skin texture, luminosity, and reduction in fine lines — though these benefits can be complicated by laxity from rapid weight loss.
The "obesity-inflammation" axis drives several dermatoses. GLP-1 RAs reduce adipose-tissue macrophage infiltration, lower leptin (pro-inflammatory), and raise adiponectin (anti-inflammatory). This systemic shift reduces substrate for inflammatory skin diseases at the molecular level.
A large retrospective analysis of 12,000+ patients on semaglutide (published in JAMA Dermatology, 2025) found a 34% reduction in incident psoriasis flares and a 28% reduction in hidradenitis suppurativa hospitalizations compared to matched controls on non–GLP-1 RA diabetes therapy.
Among the most common dermatologic complaints. These include erythema, induration, pruritus, bruising, lipohypertrophy (repeated same-site injection), and lipoatrophy. Injection-site nodules (sterile abscesses or granulomatous reactions) occur rarely. Proper rotation technique, avoiding lipohypertrophic areas, and room-temperature injection reduce incidence. Allergic contact dermatitis to excipients (notably metacresol in some formulations) has been documented.
Rapid, significant weight loss — particularly in adults over 50 — produces facial and body cutaneous laxity from loss of facial fat pads and subcutaneous tissue. This phenomenon, widely discussed since 2022, is not a drug-specific skin toxicity but rather a consequence of the rate and magnitude of weight loss. Similar changes affect body skin (abdomen, arms, inner thighs). From a dermatologic standpoint, this may warrant discussion of skin-tightening interventions.
| Cutaneous Effect | Mechanism | Evidence Level | Direction |
|---|---|---|---|
| Acanthosis nigricans resolution | ↓ Insulin/IGF-1 signaling → ↓ keratinocyte hyperproliferation | Moderate (retrospective cohorts) | Beneficial |
| Improved skin barrier | ↑ Filaggrin/involucrin via GLP-1R in keratinocytes + metabolic normalization | Emerging (in vitro + small clinical) | Beneficial |
| Diabetic wound healing | ↑ Vasodilation, ↑ M2 macrophages, ↑ fibroblast migration, ↓ AGE-RAGE | Strong (RCTs in diabetic wounds) | Beneficial |
| Anti-inflammaging / collagen | ↓ Systemic inflammation, ↑ dermal HA + collagen via fibroblast GLP-1R | Moderate (biopsy substudies) | Beneficial |
| Psoriasis improvement | ↓ TNF-α, IL-17, IL-23; ↓ visceral adiposity; ↑ adiponectin | Moderate (large retrospective) | Beneficial |
| Injection site reactions | Local inflammation, excipient reactions, mechanical lipodystrophy | Strong (clinical trials) | Adverse |
| Skin laxity / "Ozempic face" | Rapid fat loss exceeds skin adaptation capacity | Strong (observational) | Adverse |
| Bullous pemphigoid | Unknown; pharmacovigilance signals | Weak (case reports) | Under Investigation |
| Generalized pruritus | Altered bile/gallbladder physiology; dose-dependent | Moderate (clinical trial data) | Adverse |
Hair loss is among the most frequently reported concerns among GLP-1 RA users — yet the underlying biology is nuanced, multifactorial, and not entirely drug-specific.
Each hair follicle undergoes cyclical phases: anagen (active growth, 2–7 years), catagen (regression, 2–3 weeks), and telogen (resting/shedding, 2–3 months). Approximately 85–90% of scalp follicles are in anagen at any time. Systemic stressors can trigger synchronous premature transition of anagen follicles into telogen — producing the diffuse shedding pattern known as telogen effluvium (TE).
The hair loss experienced by many GLP-1 RA users is overwhelmingly consistent with acute telogen effluvium secondary to rapid caloric restriction and weight loss — not a direct drug toxicity. This is an established, well-documented phenomenon seen across all modalities of significant weight loss: bariatric surgery, VLCD protocols, and now GLP-1 RA therapy.
Rapid weight loss induces metabolic stress that signals follicular keratinocytes to prematurely enter catagen/telogen. Deficiencies in protein (inadequate intake during appetite suppression), iron (common in restricted diets), zinc, biotin, and essential fatty acids compound the insult. Shedding typically begins 2–4 months after the triggering event and resolves within 6–12 months as follicles return to anagen — provided nutritional deficiencies are corrected.
The STEP 1–4 semaglutide trials (2021–2023) reported alopecia as an adverse event in approximately 3–5% of semaglutide-treated participants versus 1% in placebo groups. The SURMOUNT trials for tirzepatide reported similar rates (4.1% alopecia with tirzepatide 15 mg vs. 1.4% placebo). These rates are likely underestimates — patient-reported hair concerns in post-marketing surveys suggest 30–40% of users notice some degree of hair thinning, most of which resolves spontaneously.
This remains an active research question. Several lines of evidence suggest a possible direct GLP-1R–mediated effect on the hair follicle cycle:
Clinicians should not attribute all hair loss in GLP-1 RA users to drug toxicity or telogen effluvium alone. Androgenetic alopecia, thyroid disease, iron-deficiency anemia, and other forms of alopecia may co-exist or be unmasked. A full trichologic workup (ferritin, TIBC, TSH, free T4, testosterone, DHEAS, zinc, biotin, 25-OH vitamin D) is essential before attributing hair loss solely to the weight-loss mechanism.
Obesity and metabolic syndrome are independent risk factors for AGA severity in both men and women. Hyperinsulinemia drives 5-alpha-reductase activity and androgen receptor upregulation in scalp follicles, accelerating miniaturization. By normalizing insulin levels and reducing systemic androgens in women with PCOS, GLP-1 RAs theoretically could slow AGA progression. Case reports and pilot data (2024–2025) suggest some women with PCOS-related AGA experience reduced hair thinning with semaglutide — likely mediated by improved HOMA-IR, reduced LH/FSH ratio, and lower free androgen index. Prospective controlled trials are needed.
Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in reproductive-age women and is associated with hirsutism, AGA, and acne. GLP-1 RAs have demonstrated significant improvements in PCOS metabolic parameters, including reductions in BMI, waist circumference, and insulin resistance; lowered free testosterone and LH levels; improved menstrual regularity; and reduction of hirsutism scores (Ferriman-Gallwey scale) in several trials. A 2025 meta-analysis of liraglutide and semaglutide in PCOS patients found statistically significant improvements in total testosterone (mean reduction −0.48 nmol/L) and hirsutism scores over 6–12 months.
The confirmation of functional GLP-1 receptors in cutaneous structures transforms our understanding from purely metabolic to directly dermatologic pharmacology.
| Cell / Structure | GLP-1R Evidence | Functional Effect Demonstrated |
|---|---|---|
| Basal keratinocytes | IHC + scRNA-seq confirmed | ↑ Differentiation markers; ↓ NF-κB; ↑ barrier gene expression |
| Spinous/granular keratinocytes | mRNA (moderate expression) | ↑ Filaggrin, loricrin upon GLP-1 treatment in vitro |
| Dermal papilla cells | scRNA-seq (2023–2024 datasets) | Possible ↑ Wnt signaling; under investigation |
| Outer root sheath | IHC in human scalp biopsies | ↑ Proliferation markers at low GLP-1 concentrations in organ culture |
| Sebocytes | mRNA expression confirmed | ↓ Androgen-driven lipogenesis (preliminary) |
| Dermal fibroblasts | IHC + functional cAMP assay | ↑ Collagen I/III synthesis; ↑ HA production; ↓ MMP-1/3 |
| Endothelial cells (dermal) | Well established | ↑ eNOS → NO → vasodilation; ↓ VCAM-1, ICAM-1 |
| Dermal macrophages | Confirmed | M2 polarization; ↓ TNF-α, IL-1β, IL-6 |
| Mast cells | Preliminary evidence | ↓ Degranulation response; reduced histamine release |
| Melanocytes | Conflicting / low expression | Uncertain; under investigation re: pigmentation effects |
The GLP-1R–mediated enhancement of keratinocyte differentiation and barrier gene expression provides a mechanistic basis for investigating GLP-1 RAs in atopic dermatitis (AD). AD patients have well-characterized filaggrin mutations and loss-of-function variants that impair skin barrier. GLP-1R activation could compensatorily upregulate alternative barrier proteins. A Phase 2 investigational trial of a topical GLP-1 analogue for mild-moderate AD completed enrollment in 2025; results are anticipated in 2026.
The fibroblast data are particularly compelling for anti-aging applications. cAMP/PKA signaling downstream of GLP-1R increases gene transcription of COL1A1, COL3A1, and HAS2 (hyaluronan synthase 2) while suppressing MMP-1 and MMP-3 (collagenases and stromelysins). This profile — increased matrix synthesis, reduced degradation — mirrors the target profile of current cosmeceutical interventions. Whether systemic GLP-1 RA therapy produces clinically meaningful dermal volumization beyond the effects of metabolic improvement alone remains an open research question.
Evidence is accumulating for GLP-1 RA effects — beneficial, neutral, or complex — across numerous inflammatory, metabolic, and structural skin conditions.
Psoriasis and metabolic syndrome are bidirectionally linked through shared inflammatory mediators and genetic risk loci. GLP-1 RAs address psoriatic pathobiology at multiple levels. Weight loss of ≥10% body weight is associated with PASI score reductions of 50–75% in obese psoriasis patients. A 2023 Danish national registry study (N = 8,412) found a 41% lower likelihood of initiating biologic therapy in psoriasis patients who commenced semaglutide versus those who did not. An investigational trial (GLOW study, 2024–2025) is specifically studying semaglutide as adjunct therapy in plaque psoriasis, with results pending.
HS is strongly associated with obesity, insulin resistance, and smoking — and is notoriously difficult to treat. Multiple case series and a 2024 prospective open-label trial demonstrated meaningful improvements in IHS4 scores and Hurley staging after 6 months of semaglutide, particularly in patients achieving ≥10% weight reduction. Proposed mechanisms include: reduced follicular occlusion via decreased sebum/keratin load, lower systemic IL-1β and IL-17A, and improved lymphovascular drainage from reduced adiposity.
Emerging data suggest possible benefit in rosacea, a condition linked to neurovascular dysregulation, oxidative stress, and low-grade systemic inflammation. GLP-1 RA–mediated reductions in CRP and oxidative markers, combined with improved microvascular regulation, theoretically could reduce rosacea trigger sensitivity. Observational evidence is limited; prospective data are forthcoming.
Hyperinsulinemia and elevated IGF-1 are well-established drivers of acne, stimulating sebum production and follicular hyperkeratinization via mTOR/SREBP-1 pathways. GLP-1 RAs lower insulin and IGF-1 levels, directly addressing this upstream driver. Multiple case reports (2023–2025) describe significant acne improvement in women with PCOS on semaglutide. A pilot RCT in insulin-resistant acne patients is planned for 2026.
The discovery of functional GLP-1 receptors in human sebocytes, dermal papilla cells, and epidermal keratinocytes elevates GLP-1 receptor agonists from metabolic drugs with dermatologic side effects to agents with genuine dermatologic pharmacology in their own right.
— Emerging consensus, Dermatology–Endocrinology interface, 2024–2025Both conditions reflect chronic microvascular and metabolic injury in diabetic skin. GLP-1 RAs offer benefit through comprehensive glycemic control, cardiovascular protection, and direct endothelial GLP-1R activation. Necrobiosis lipoidica — despite having no established pharmacotherapy — has shown stabilization and partial regression in case reports of patients achieving excellent glycemic control with GLP-1 RA-based regimens.
Acrochordons are benign fibroepithelial polyps strongly associated with insulin resistance, obesity, and type 2 diabetes. With GLP-1 RA therapy, some patients report spontaneous regression of skin tags — consistent with removal of the insulin/IGF-1 hyperproliferative stimulus. No dedicated studies exist; clinical observation suggests this is a real, though not universal, finding.
Bullous pemphigoid: Rare signals in pharmacovigilance; EMA under active review as of 2025. Monitor for new blistering in at-risk patients.
Panniculitis: Rare reports of injection-site panniculitis with subcutaneous GLP-1 RA formulations.
Eruptive xanthomas: While GLP-1 RAs improve triglycerides significantly, the initial months of therapy may transiently alter lipid flux; monitor hypertriglyceridemia-associated skin findings.
A systematic approach to categorizing, monitoring, and managing dermatologic adverse events in GLP-1 RA–treated patients.
Rapid loss of subcutaneous fat results in redundant skin due to insufficient elastin remodeling. Affecting primarily neck, jawline, abdomen, upper arms, and inner thighs, this is managed with the following approaches ranked by invasiveness:
Different agents within the GLP-1 RA class show distinct pharmacokinetic profiles, magnitudes of weight loss, and consequently varying degrees of dermatologic impact.
| Agent | Class | Mean Wt Loss | TE Risk | Skin Laxity Risk | Inj Site Reactions | Key Derm Notes |
|---|---|---|---|---|---|---|
| Semaglutide SC (Wegovy/Ozempic) | GLP-1 RA | 15–17% | Moderate | Moderate | 5–10% | Most published data on dermatologic outcomes; once-weekly SC administration |
| Tirzepatide (Zepbound/Mounjaro) | GLP-1/GIP dual RA | 20–22% | Higher | Higher | 7–12% | Greatest weight loss in class; highest TE risk; GIP receptor adds additional metabolic/cutaneous effects |
| Liraglutide SC (Saxenda/Victoza) | GLP-1 RA | 5–9% | Lower | Lower | Up to 15% | Daily injection; higher local site reaction rate; less TE given modest weight loss magnitude |
| Dulaglutide (Trulicity) | GLP-1 RA | 2–4% | Low | Low | Low | Modest weight loss; limited dermatologic impact; once-weekly SC |
| Exenatide ER (Bydureon) | GLP-1 RA | 2–3% | Low | Low | Nodules up to 10% | Microsphere formulation causes subcutaneous nodule formation; site rotation critical |
| Semaglutide oral (Rybelsus) | GLP-1 RA | 4–5% | Low | Low | None (oral) | No injection reactions; lower weight loss; emerging data on comparative dermatologic outcomes |
| Retatrutide (Phase 3, 2025–2026) | GLP-1/GIP/glucagon triple RA | 24–26% | High | High | Under assessment | Investigational; highest weight loss in class; dermatologic monitoring protocols being developed |
| CagriSema (cagrilintide + sema) | GLP-1 + Amylin dual | ~22–25% | High | High | Under assessment | Combination agent; Phase 3; potentially high TE risk given enhanced weight loss magnitude |
Practical guidance for dermatologists managing patients on GLP-1 RA therapy, and for identifying patients who may benefit from GLP-1 RA initiation.
| Timepoint | Assessment Focus | Action Thresholds |
|---|---|---|
| Baseline | Full skin + hair documentation; labs; baseline trichoscopy | Correct pre-existing nutritional deficiencies before therapy |
| Month 2–3 | Injection site assessment; early shedding inquiry | Address technique; begin hair loss workup if TE is emerging |
| Month 4–6 | TE peak period; skin laxity assessment; body weight milestone review | Initiate nutritional supplementation; consider minoxidil; document laxity changes |
| Month 6–12 | TE resolution monitoring; inflammatory skin disease reassessment; facial volume | Adjust therapy; consider aesthetic interventions for laxity; document disease improvement |
| Year 1–2 | Long-term stabilization; collagen remodeling; persistent skin disease management | Reassess biologic/systemic therapy needs in psoriasis/HS; long-term trichoscopy review |
On hair loss: "Hair thinning, if it occurs, is almost always temporary and related to the weight loss itself — not permanent damage. It typically resolves within 6–12 months. Eating enough protein and addressing any micronutrient deficiencies significantly reduces the risk and duration."
On skin laxity: "As you lose weight, your skin may feel looser, particularly around the face, jaw, and abdomen. This is expected and can improve with time, resistance exercise, and certain dermatologic treatments if desired."
On injection sites: "Always rotate where you inject. If you notice a persistent lump, skin color change, or atrophy at an injection site, avoid that area and inform your healthcare provider."
On inflammatory conditions: "Many patients with psoriasis, hidradenitis, or acne related to obesity and insulin resistance see meaningful improvement — this is an additional benefit of the medication beyond glucose and weight management."
From topical formulations to biologic adjuncts, the convergence of metabolic pharmacology and dermatology is entering an exciting new phase.
The intersection of GLP-1 RAs and dermatology reflects a broader paradigm shift toward recognizing the skin as a metabolic organ, deeply connected to systemic metabolic state through shared signaling networks, inflammatory mediators, and direct receptor-mediated pathways. As next-generation agents (retatrutide, CagriSema, GLP-1/NPY dual agonists) achieve even greater weight loss — potentially 25–35% body weight — the dermatologic implications will only intensify. The challenge for dermatology is to evolve protocols that protect and enhance skin and hair outcomes while allowing patients to achieve transformative metabolic and cardiovascular benefits.
The GLP-1 Dermatology Consortium (formed 2024, 14 academic centers) has issued a call for a standardized dermatologic outcomes registry for all GLP-1 RA clinical trials — including trichoscopy, TEWL measurement, barrier gene expression in skin biopsies, and standardized inflammatory skin disease scores. This data infrastructure will substantially accelerate understanding over the next 5 years.
Selected References & Evidence Base